Bayer Q3 2024 Media Update

Strategic progress in challenging business environment – Group outlook confirmed in nearly all parameters 

• • Group sales at 9.968 billion euros (Fx & portfolio adj. plus 0.6 percent) 

• EBITDA before special items at 1.251 billion euros (minus 25.8 percent)

• • Core earnings per share at 0.24 euros (minus 36.8 percent)

• • Net income at minus 4.183 billion euros, impairment losses at Crop Science 

• • Free cash flow at 1.148 billion euros 

• • 2024 Group outlook confirmed for sales growth (Fx & portfolio adj.), core earnings per share and free cash flow – reduced market dynamics in agricultural business, lower growth expected for consumer health market, Pharmaceuticals at higher end of guidance 

• • 2025: Regulatory challenges and generic price pressure in crop protection business, new products to mitigate patent loss impact in Pharmaceuticals, robust growth expected at Consumer Health

• • Successful advancements in bolstering the Pharmaceuticals pipeline and leveraging the new operating model 

• • Bill Anderson: “We're tackling challenges head on and making progress on our strategic priorities” 

NEWS RELEASE